Thorne HealthTech Acquires PreCon Health

L Catterton Completes Acquisition of Thorne HealthTech, Inc.

October 16, 2023

Healthcare Services

L Catterton has completed its acquisition of Thorne HealthTech, Inc. through a tender offer and subsequent second‑step merger, paying $10.20 per share and taking Thorne private. Thorne's common stock will be delisted from the Nasdaq and L Catterton intends to support Thorne's growth and execution of its clinically backed personalized testing and supplement offerings.

Thorne HealthTech Acquires Majority of Drawbridge Health

May 25, 2021

Medical Devices

Thorne HealthTech acquired a majority of outstanding shares of Drawbridge Health, the developer of the OneDraw blood collection device and A1C Test System. Drawbridge Health will remain a majority‑owned and controlled subsidiary, with its former CEO Lee McCraken staying on as chairman while new co‑CEOs lead growth and integration efforts.

2B Associates Acquires PreMark Health Science

October 8, 2024

Manufacturing

2B Associates has acquired PreMark Health Science, a Texas-based manufacturer of nutraceutical, cosmeceutical and OTC products, to vertically integrate manufacturing capabilities and accelerate product development for its pet wellness brand Carson & Bear. Scott Steinford, founder and chairman of 2B Associates, will become CEO of PreMark Health Science as the combined company scales production and brings new pet health products to market faster.

Astorg Takes Hamilton Thorne Private and Acquires Cook Medical Reproductive Health

December 2, 2024

Medical Devices

Astorg completed a take-private of Hamilton Thorne and simultaneously acquired Cook Medical’s Reproductive Health business, combining the two to create a global leader in assisted reproductive technology (ART) consumables, instruments and equipment. The combined company will serve fertility clinics and IVF laboratories in over 115 countries, with a new executive team appointed to lead the integrated MedTech platform.

Concentra Biosciences (Tang Capital) to Acquire Theseus Pharmaceuticals

December 22, 2023

Biotechnology

Concentra Biosciences, a vehicle controlled by Tang Capital Partners, has entered into a definitive merger agreement to acquire clinical-stage biotech Theseus Pharmaceuticals for $3.90–$4.05 per share in cash plus a contingent value right tied to future program licensing/disposition proceeds. The transaction will be effected by a tender offer and is expected to close in February 2024, subject to customary conditions and the availability of required cash at closing.

Prescient Acquires Strategic North

March 2, 2022

Consulting

Prescient, a PE-backed biopharma product and portfolio strategy consultancy, has acquired Strategic North, a UK-based commercial strategy and brand research consultancy serving pharmaceutical and biotech clients. The acquisition is an add-on to Prescient’s platform intended to deepen its commercial and brand strategy capabilities for global pharma and biotech customers.